Another string to the bow in global pandemic fight

12 March 2021

Positive Phase III data from East Coast, USA-based vaccine specialist Novavax (Nasdaq: NVAX) could soon pave the way for another approved option against the novel coronavirus.

Final efficacy numbers from a large UK-based study show the candidate was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain.

Less encouragingly, a different set of results from a Phase IIb trial in South Africa show efficacy of 55.4% - the majority of strains in this region are of the B1.351 type.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK